Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Galapagos and Janssen part ways following 'therapeutic shift'

This article was originally published in Scrip

Executive Summary

Galapagos, which said in December that its partnership with Janssen Pharmaceutica was "very much alive," now says the companies have agreed to mutually terminate their inflammation alliance and option agreements. "The therapeutic indications of these programs have shifted along the way and moved outside focus areas of Janssen," Galapagos CEO Onno van de Stolpe told Scrip.

Advertisement

Related Content

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC028141

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel